Perioperative management of antiplatelet-drugs in cardiac surgery

Current Cardiology Reviews

Volumn 5, Issue 2, 2009, Pages 125-132

  Ferrandis, Raquel ^a   Llau, Juan V ^a   Mugarra, Ana ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE PHOSPHATE; ANTITHROMBOCYTIC AGENT; APROTININ; CLOPIDOGREL; CYCLOOXYGENASE 1; DESMOPRESSIN; DIPYRIDAMOLE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; ILOPROST; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTACYCLIN; TICLOPIDINE; TIROFIBAN; TRANEXAMIC ACID;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; BLEEDING; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG HALF LIFE; DRUG MEGADOSE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LOADING DRUG DOSE; LOW DRUG DOSE; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; PERIOPERATIVE PERIOD; POSTOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; SINGLE DRUG DOSE; ST SEGMENT ELEVATION; SYSTEMATIC REVIEW; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; THROMBOCYTE TRANSFUSION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT INDICATION; TREATMENT WITHDRAWAL;

EID: 68449089409     PISSN: 1573403X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340309788166688     Document Type: Review

References (86)

1. Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26: 804-47.
2. Popma JJ, Berger P, Ohman EM, Harrington RA, Grines C, Weitz JL. Antithrombotic therapy durin percuraneous coronary intervention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 576S-99S.
3. Bojar RM. In: Manual of Perioperative Care in Adult Cardiac Surgery. Blackwell, Malden, Oxford, 2005
4. Collet JP, Montalescot G, Balnchet B, et al. Impact of prior use or recent withdrawal of oral antiplatet agents on acute coronary syndromes. Circulation 2004; 110: 2361-67.
5. Ia Kovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors and aoutcomme of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293; 2126-30.
6. Ferrari E, Benhamou M, Cerboni P, Marcel B. Coronary syndromes following aspirin withdrawal: an especial risk for late stent thrombosis. J Am Coll Cardiol 2005; 45: 456-9.
7. Samama CM, Bastien O, Forestier F, et al. Antiplatelet agents in the perioperative period: expert recommendations of the French Society of Anesthesiology and Intensive Care (SFAR) 2001 - Summary statement. Can J Anesth 2002; 49: S26-S35.
8. Lecompte T, Hardy JF. Antiplatelet agents and perioperative bleeding. Can J Anesth 2006; 53: S103-S12.
9. Patrono C, Coller B, Fitzgerald GA, Hirsh J, Roth G. Platelet active drugs: the relationships among dose, effectiveness and side effects. Chest 2004; 126: 234S-64S.
10. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin. Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119: 64S-94S.
11. L'Allier PL, Ducrocq G, Pranno N, et al. Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens. Results from PREPAIR randomized study. J Am Coll Cardiol 2008; 51: 1066-72.
12. Servin F. Low-dose aspirin and clopidogrel: how to act in patients scheduled for day surgery. Curr Opin Anaesthesiol 2007; 20: 531-4.
13. Albaladejo P, Marret E, Piriou V. Samama CM. Perioperative management of antiplatelet agents in patients with coornary stents: recommendations of a French Task Force. Br J Anaesth 2006; 97: 580-84.
14. Dalal AR, D'Souza S, Shulman RS. Brief review: Coronary drug-eluting stents and anesthesia. Can J Anesth 2006; 53: 1230-43.
15. The Task Force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European Society of Cardiology. Espert consensus document on the use of antiplatelet agents. Eur Heart J 2004; 25: 166-81.
16. Guyatt G, Schunëmann H, Cook D, et al. Grade of recommendation for antithrombotic agents. Chest 2001; 119: 3S-7S.
17. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention ofdeath, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
18. Sun JCJ, Whitlock RW, Cheng J, et al. The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observatina studies. Eur Heart J 2008; 1057-71.
19. Jimenez AH, Stubbs ME, Tofler GH, Winther K, Williams GH, Muller JE. Rapidity and duration of platelet suppression by enteric-coated aspirin in healthy young men. Am J Cardiol 1992; 69: 258-62.
20. McDonald JW, Ali M. Recovery of cyclooxigenase activity after aspirin in populations of platelets separated on stractan density gradients. Prostaglandins Leukot Med 1983; 12: 245-52.
21. Beving H, Zhao C, Albage A, Ivert T. Abnormally high platelet activity after discontinuation of acetylsalicylic acid treatment. Blood Coagul Fybrinolysis 1996; 7: 80-4.
22. Ferrari E, Benhamou M, Cerboni P, Marcel B. Coronary syndromes following aspirin withdrawal, a special risk for late stent thrombosis. J Am Coll Cardiol 2005; 45: 456-9.
23. Collet JP, Himbert F, Steg PG. Myocardial infarction after aspirin cessation in stable coronary artery disease patients. Int J Cardiol 2000; 76: 257-8.
24. Burguer W, Chemnitius JM, Kneissl GD, Rucker G. Low-dose aspirin for secondary cardiovascular prevention -cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation- review a meta-analysis. J Intern Med 2005; 257: 399-414.
25. Fox KA, Mehta SR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non ST-elevtion acute coronary syndrome: th Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004; 110: 1202-8.
26. Ho PM, Peterson ED, Wang L, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 2008; 299: 532-9.
27. Thurston AV, Briant SL. Aspirin and post-prostatectomy haemorrhage. Br J Urol 1993; 71: 574-6.
28. Palmer JD, Sparrow OC, Ianotti F. Postoperative hematoma: a 5-year survey and identification of avoidable risk factors. Neurosurgery 1994; 35: 1061-4.
29. Weightman WM, Gibbs NM, Weidmann CR, et al. The effect of preoperative aspirin-free interval on red blood cell tansfusion requirements in cardiac surgical patients. J Cardiothorac Vasc Anesth 2002; 16: 54-8.
30. Lindblad B, Persson NH, Takolander R, Bergqvist D. does low dose acetylsalicylic acid prevent stroke after carotid surgery? A double-blind, placebo-controlled randomized trial. Stroke 1993; 24: 1125-8.
31. Kallis P, Tooza JA, Talbot S, Cowans D, Bevan DH, Treasure T. Preoperative aspirin decreases platelet aggregation and increases post-operative blood loss -a prospective, randomized, placebo controlled, double-blind clinical trial in 100 patients with chronic stable angina. Eur J Cardiothorac Thorac Surg 1994; 8: 404-9.
32. Morawski W, Sanak M, Cisowski M, et al. Prediction of the excessive perioperative bleeding in patients undergoing coronary artery bypass grafting: role of aspirin and platelet glycoprotein IIIa polymorphism. J Thorac Cardiovasc Surg 2005; 130: 791-6.
33. Sethi GK, Copeland JG, Goldman S, Moritz T, Zadina K, Henderson WG. Implications of preoperative administration of aspirin in patients undergoing coronary artery bypass grafting. Department of veterans Affairs Cooperative Study on Antiplatelet Therapy. J Am Coll Cardiol 1990; 15: 15-20.
34. Rawitscher RE, Jones JW, McCoy TA, Lindsley DA. A prospective study of aspirin's effect on red blood cell loss in cardiac surgery. J Cardiovasc Surg 1991; 32: 1-7.
35. Reich DL, Patel GC, Vela-Cantos F, Bodian C, Lansman S. Aspirin does not increase homologous blood requirements in elective coronary bypass surgery. Anesth Analg 1994; 79: 4-8.
36. Vuylsteke A, Oduro A, Cardan E, Latimer RD. Effects of aspirin in coronary artery bypass grafting. J Cardiothorac Vasc Anaesth 1997; 11: 831-4.
37. Sun JCJ, Whitlock R, Cheng J, et al. The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observational studies. Eur Heart J 2008; 29: 1057-71.
38. Alghamdi AA, Moussa F, Fremes SE. Does the use of preoperative aspirin increase the risk of bleeding in patients undergoing coronary artery bypass grafting surgery? Systematic review and metaanalysis. J Card Surg 2007; 22: 247-56.
39. Srinivasan AK, Grayson AD, Pullan DM, Fabri BM, Dihmi WC. Effect of preoperative aspirin use in off-pump coronary artery bypass operations. Ann Thorac Surg 2003; 76: 41-5.
40. Shim JK, Choi YS, Oh YJ, Bang SO, Yoo KJ, Kwak YL. Effects of preoperative aspirin and clopidogrel therapy n perioperative blood loss and blood transfusion requirements in patients undergoing off-pump coronary artery bypass graft surgery. J Thorac Cardiovasc Surg 2007; 134: 59-64.
41. Dacey LJ, Munoz JJ, Johnson ER, et al. Effect of preoperative aspirin use on mortality in coronary artery bypasses grafting patients. Ann Thorac Surg 2000; 70: 1986-90.
42. Bybee KA, Powell BD, Valeti U, et al. Preoperative aspirin therapy is associated with improved postoperative outcomes in patients undergoing coronary artery bypass grafting. Circulation 2005; 112: 286-92.
43. Tuman KJ, McCarthy RJ, O'Connor CJ, McCarthy WE, Ivankovich AD. Aspirin does not increase allogenic blood transfusion in reoperative coronary artery surgery. Anesth Analg 1996; 83: 1178-84.
44. Karthik S, Grayson AD, McCarron EE, Pullan DM, Desmond MJ. Reexploration for bleeding after coronary artery bypass surgery: risk factors, outcomes, and the effect of time delay. Ann Thorac Surg 2004; 78: 527-34.
45. Yende S, Wunderink RG. Effect of clopidogrel on bleeding after coronary artery bypass surgery. Crit Care Med 2001; 29: 2271-5.
46. Leong JY, Baker RA, Shah PJ, Cherian VK, Knight JL. Clopidogrel and bleeding after coronary artery bypass graft surgery. Ann Thorac Surg 2005; 80: 928-33.
47. Kapetantakis EI, Medlam DA, Petro KR, et al. Effect of clopidogrel premedication I off-pump cardiac surgery: are we forfeiting the benefits or reduced hemorrhagic squeal? Circulation 2006; 113: 1667-74.
48. Von Heyman C, Redlich U, Moritz M, et al. Aspirin and clopidogrel taken until 2 days prior to coronary artery bypass graft surgery is associated with increased postoperative drainage loss. Thorac Cardiovasc Surg 2005; 53: 341-5.
49. Kang W, Theman TE, Reed JF, Stoltzfus J, Weger N. The effect of preoperative clopidogrel on bleeding after coronary artery bypass surgery. J Surg Educ 2007; 64: 88-92.
50. Karabulut H, Toraman F, Evrenkaya S, Goksel O, Tarcan S, Alhan C. Clopidogrel does not increase bleeding and allogenic blood transfusion in coronary artery surgery. Eur J Cardiothorac Surg 2004; 25: 419-23.
51. Reichert MG, Robinson AH, Travis JA, Hammon JW, Kon ND, Kincaid EH. Effects of a waiting period after clopidogrel treatment before performing coronary artery bypass grafting. Pharmacotherapy 2008; 28: 151-5.
52. Bavry AA, Lincoff AM. Is clopidogrel cardiovascular Medicine's double-edged sword? (Editorial). Circulation 2006; 113: 1638-40.
53. Pothula A, Sanchala VT, Nagappala B, Inchiosa MA. The effect on preoperative antiplatelet/anticoagulant prophylaxis on postoperative blood loss in cardiac surgery. Anesth Analg 2004; 98: 4-10.
54. Kleiman NS. Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors. Am Heart J 1999; 138: 263-75.
55. Tcheng JE. Differences among the parenteral platelet glycoprotein IIb/ IIIa inhibitors and implications for treatment. Am J Cardiol 1999; 83: 7E-11E.
56. Marso SP, Bhatt DL, Roe MT, et al. Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting. Circulation 2000; 102: 2952-8.
57. Dyke CM, Bhatia D, Lorentz TJ, et al. Immediate coronary artery bypass surgery after platelet inhibition with eptifibatatide: results from PURSUIT. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrelin therapy. Ann Thorac Surg 2000; 70: 866-71.
58. Bizarri F, Scolleta D, Tucci E, et al. Perioperative use of tirofiban hydrocloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting. J Thorac Cardiovasc Surg 2001; 122: 1181-5.
59. Shanmugan G. Tirofiban and emergency coronary surgery Eur J Cardiothorac Surg 2005; 28: 546-50.
60. Cheng DK, Jackevivius CA, Seidelin P, Feindel C, Rouleau JL. Safety of glycoprotein IIb/IIIa inhibitors in urgent or emergency coronary artery bypass graft surgery. Can J Cardiol 2004; 20: 223-8.
61. Silvestry SC, Smith PK. Current status of cardiac surgery in the abciximab-treated patient. Ann Thorac Surg 2000; 70: S12-9.
62. Le Narz LA. Coronary artery bypass in abciximab-treated patients. Ann Thorac Surg 2000; 70: S38-42.
63. De Carlo M, Maselli D, Cortese B, et al. Emergency coronary artery bypass grafting in patients with acute myocardial infarction treated with glycoprotein IIb/IIIa receptor inhibitors. Int J Cardiol 2008; 123; 229-33.
64. Lincoff AM, LeNArz LA, Despotis GJ, et al. Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. Improve long-term outcome with abciximab GP IIb/IIIa blockade. Evaluation of platelet IIb/IIIa inhibition in STENTing. Ann Thorac Surg 2000; 70: 516-26.
65. Sedrakyan A, Treasure T, Elefteriades JA. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg 2004; 128: 442-48.
66. Mangano DT, Tudor IC, Dietzel C. The risk assocaited with aprotinin in cardiac surgery. N Engl J Med 2006; 354: 353-65.
67. Schneeweiss S, Seeger JD, Landon J, Walker AM. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med 2008; 358: 771-83.
68. Shaw AD, Stafford-Smith M, White WD, et al. The effect of aprotinin on outcome after coronary artery bypass grafting. N Engl J Med 2008; 358: 784-93.
69. Have1 M, Grabenwoger F, Schneider J, et al. Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood. J Thorac Cardiovasc Surg 1994; 107: 807-10.
70. Kalangos A, Tayyareci G, Pretre R, Di Dio P, Sezerman O. Influence of aprotinin on early graft thrombosis in patients undergoing myocardial revascularization. Eur J Cardiothorac Surg 1994; 8: 651-6.
71. Lemmer JH Jr, Stanford W, Bonney SL, et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency-a multicenter, randomized, double-blind, placebo-controlled study. J Thorac Cardiovas Surg 1994; 107: 543-51.
72. Pleym H, Stenseth R, Wahba A, et al. Prophylactic treatment with desmopressin does not reduce postoperative bleeding after coronary surgery in patients treated with aspirin before surgery. Anesth Analg 2004; 98: 578-84.
73. Casati V, Della Valle P, Benussi S, et al. Effects of tranexamic acid on postoperative bleeding and related hematochemical variables in coronary surgery: comparison between on-pump and off-pump techniques. J Thorac Cardiovasc Surg 2004; 128: 83-91.
74. Andreasen JJ, Nielsen C. Prophylactic tranexamic acid in elective, primary coronary artery bypass surgery using cardiopulmonary bypass. Eur J Cardiothorac Surg 2004; 26: 311-7.
75. Santos ATL, Kalil RAK, Bauemann C, Pereira JB, Nesralla IA. A randomized, double-blind, and placebo-controlled study with tranexamic acid of bleeding and fibrinolytic activity after primary coronary artery bypass grafting. Braz J Med Biol Res 2006; 39: 63-9.
76. Pleym H, Stenseth R, Wahba A, Bjella L, Karevold A, Dale O. Single-dose tranexamic acid reduces postoperative bleeding after coronary surgery in patients treated with aspirin until surgery. Anesth Analg 2003; 96: 923-8.
77. Sié P, Steib A. Central laboratory and point of care assessment of perioperative hemostasis. Can J Anesth 2006; 53: S12-20.
78. Howard-Alpe GM, de Bono J, Hudsmith L, Orr WP, Foex P, Sear JW. Coronary artery stents and con-cardiac surgery. Br J Anaesth 2007; 98: 560-74.
79. Craft RM, Chavez JJ, Snider CC, Muenchen RA, Carroll RC. Comparison of modified thrombelastograph and plateletworks whole blood assays to optical platelet aggregation for monitoring reversal of clopidogrel inhibition in elective surgery patients. J Lab Clin Med 2005; 145: 309-15.
80. Lennon MJ, Gibbs NM, Weigthman WM, McGuire D, Michalopoulos N. A comparison of Plateletworks™ and platelet aggregometry for the assessment of aspirin-related platelet dysfunction in cardiac surgical patients. J Cardiothorac Vasc Anesth 2004; 18: 136-40.
81. Essell JH, Martin TJ, Salinas J. Comparison of thromboelastography to bleeding time and standard coagulation tests in patients after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1993; 7: 410-5.
82. Hertfelder HJ, Bös M, Weber D, Winkler K, Hanfland P, Preusse CJ. Perioperative monitoring of primary and secondary haemostasis in coronary artery bypass grafting. Semin Thromb Hemost 2005; 31: 426-40.
83. Ferraris VA, Ferraris SP, Saha SP, et al. Perioperative blood transfusion and blood conservation in cardiac surgery: The society of thoracic surgeons and society of cardiovascular anesthesiologists clinical practice guideline. Ann Thorac Surg 2007; 83: S27-86.
84. Chassot PG, Delabays A, Spanh DR. Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction. Br J Anaesth 2007; 99: 316-28.
85. Dunning J, Versteegh M, Fabbri A, et al. Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur J Cardiothorac Surg 2008; 34: 73-92.
86. Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy. Chest 2008; 133: 299-339S.